While the target gene APP is identified as a target of Florbetapir F-18, this drug’s primary use currently lies in diagnostic imaging, specifically as a radiopharmaceutical compound in PET scans to visualize amyloid plaques, a key indicator of Alzheimer’s Disease [58]. Here, APP is linked to early-onset autosomal dominant Alzheimer disease.